Innocan Pharma Corporation reported the successful completion of Innocan's CBD Liposome drug-product physico-chemical characterization. Physico-chemical characterization is an important part of the application package to be submitted to the FDA. It is also a crucial milestone towards a potential submission of an Investigational New Drug Application and New Drug Application of Innocan's liposomal CBD drug product file following completion of toxicology, pharmacokinetics and efficacy studies.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.28 CAD | +1.82% | +3.70% | -9.68% |
1st Jan change | Capi. | |
---|---|---|
-9.68% | 57.41M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- INNO Stock
- News InnoCan Pharma Corporation
- InnoCan Pharma Corporation Reports Successful FDA Required Characterization of Highly CBD Loaded Liposome Platform